SI
SIGY.US Sigyn Therapeutics Inc
- Market cap
- USD 146K
- P/E
- -
- P/B
- 39.04x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.
Is SIGY.US undervalued?
Graham numberThe Graham number of Sigyn Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sigyn Therapeutics Inc fundamental analysis
No fundamental analysis for Sigyn Therapeutics Inc yet.
Sigyn Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sigyn Therapeutics Inc
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging …
Full company profileSigyn Therapeutics Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sigyn Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.28M | 28.3K | 143K | 9.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 772K | 18.6K | 108K | 6.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.43M | -1.00M | -518K | -916K | -2.01M | -2.15M | -2.46M | -2.52M | -1.87M |
| EBITDA | -3.22M | -1.70M | -3.18M | -905K | -2.53M | -2.14M | -2.09M | -2.47M | -3.01M |
| Net Income | -4.25M | -2.62M | -3.07M | -1.26M | -3.00M | -2.93M | -4.15M | -3.34M | -3.60M |
| EPS | -12 | -4.84 | -5.67 | -0.04 | -0.08 | -3.06 | -3.22 | -2.08 | -2.24 |
| Balance Sheet | |||||||||
| Total Assets | 2.07M | 862K | 642K | 694K | 710K | 333K | 322K | 214K | 136K |
| Total Liabilities | 4.16M | 4.58M | 3.10M | 595K | 975K | 2.24M | 3.73M | 4.67M | 6.05M |
| Shareholders' Equity | -2.09M | -3.72M | -2.46M | 99.2K | -265K | -1.90M | -3.41M | -4.46M | -5.92M |
| Cash & Short-term Investments | 9.59K | 7.50K | 500.00 | 84.4K | 341K | 8.36K | 11.7K | 12.1K | 85.6K |
| Cash Flow | |||||||||
| Operating Cash Flow | -400K | -286K | -830K | -830K | -1.77M | -1.83M | -1.38M | -872K | -862K |
| Capital Expenditure | 79.1K | 8.45K | 29.3K | 29.3K | 29.3K | 860.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -479K | -295K | -144K | -841K | -1.80M | -1.83M | -1.38M | -872K | -862K |
| Ratios | |||||||||
| ROE | - | - | - | -1,270.0% | - | - | - | - | - |
| ROA | -205.3% | -304.0% | -478.8% | -181.5% | -423.0% | -880.1% | -1,288.3% | -1,562.9% | -2,653.7% |
| Net Profit Margin | -331.0% | -9,243.2% | -2,145.3% | -12,686.0% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sigyn Therapeutics Inc dividends
Sigyn Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:40 on Jan 31, 2024.
Who owns Sigyn Therapeutics Inc
- Insiders 21.01%
- Institutions 2.55%
- Public & others 76.44%
- Shares outstanding 5.40M
- Free float 1.26M
Sigyn Therapeutics Inc company profile
- Company name
- Sigyn Therapeutics Inc
- Ticker
- SIGY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 2468 Historic Decatur Road, San Diego, CA, United States, 92106
- Phone
- 619 353 0800
- Website
- sigyntherapeutics.com
About Sigyn Therapeutics Inc
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the performance of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
Sigyn Therapeutics Inc management
2- Mr. James A. Joyce Ph.D.Co-Founder, Chairman, CEO, Inventor & Interim CFO · born 1962
- Mr. Craig P. RobertsCo-Founder, CTO & Director · born 1954